Insurancenewsnet.com

Branded Direct-to-Consumer Advertising Likely to Provide a Bump in Patient Requests for Sanofi/Regeneron’s Dupixent, but Insurance Coverage and…

Lack of insurance coverage continues to be the most commonly cited barrier to use, while out-of-pocket costs have become a growing concern amongst dermatologists. Those with ample experience with the ...
FiercePharma

Sanofi, Regeneron score their 7th indication for Dupixent with FDA nod to treat hives condition

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent has experienced few setbacks. One came in 2023, however, when the FDA ...
Nasdaq

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Nasdaq

Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria (“CSU”) in adults and adolescents aged 12 years and above, ...
FierceBiotech

Dupixent for cancer? Researchers test blockbuster med as an immunotherapy-booster

Regeneron and Sanofi’s blockbuster Dupixent has conquered numerous anti-inflammatory indications. New research in mice now suggests that the monoclonal antibody could have a future as an immunology ...